Literature DB >> 10569562

Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.

H Lilja1, A Haese, T Björk, M G Friedrich, T Piironen, K Pettersson, E Huland, H Huland.   

Abstract

PURPOSE: We studied plasma concentrations and elimination rates of prostate specific antigen (PSA) complexed to alpha1-antichymotrypsin and alpha2-macroglobulin, free PSA, total PSA (free PSA plus PSA alpha1-antichymotrypsin) and human glandular kallikrein 2 before, during and after radical retropubic prostatectomy for clinically localized prostate cancer.
MATERIALS AND METHODS: Plasma was collected and frozen within 10 minutes after sampling from 18 patients undergoing radical retropubic prostatectomy for prostate cancer. One sample was drawn preoperatively. Subsequent sampling intervals were 5 to 20 minutes perioperatively, 2 to 4 hours during the first 12 postoperative hours and 24 to 48 hours until postoperative day 14. Free PSA, PSA alpha1-antichymotrypsin, total PSA, PSA alpha2-macroglobulin and human glandular kallikrein 2 were measured with time resolved immunofluorometric assays.
RESULTS: Preoperatively PSA alpha2-macroglobulin was undetectable (less than 2 ng./ml.) in 17 of 18 patients. Human glandular kallikrein 2, free PSA and total PSA but not PSA alpha1-antichymotrypsin were significantly higher in patients with extraprostatic cancer (pT3a-pT4a, pN1) compared to those with organ confined cancer (pT2a/b). Surgical manipulation of the prostate caused no detectable elevation of human glandular kallikrein 2, PSA alpha1-antichymotrypsin or PSA alpha2-macroglobulin. In contrast, a mean 9.6-fold increase (range 3.4 to 22) in free PSA was noted 5 minutes after prostatectomy. Free PSA was eliminated from plasma in a biphasic exponential pattern with an early plasma half-life of 55 minutes and a late plasma half-life of 18 hours. PSA alpha1-antichymotrypsin decreased slowly, whereas human glandular kallikrein 2 was detectable only 12 hours after prostatectomy. PSA alpha2-macroglobulin remained at insignificant, nondetectable concentrations during the entire perioperative and postoperative period.
CONCLUSIONS: Release of free PSA contributes to the elevation of plasma total PSA after prostatectomy. Free PSA is enzymatically inactive as the release does not result in subsequent elevation of PSA alpha1-antichymotrypsin or PSA alpha2-macroglobulin. Biphasic exponential elimination of free PSA may be explained by rapid extracellular redistribution (early half-life) and glomerular filtration in the kidneys (late half-life). Our data suggest rapid metabolism of human glandular kallikrein 2 but do not support suggestions of the significance in vivo of complex formations with alpha2-macroglobulin as a major means to eliminate PSA from plasma in patients with clinically localized prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569562     DOI: 10.1016/s0022-5347(05)68093-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.

Authors:  Michael A Maccini; Nicholas J Westfall; Adrie Van Bokhoven; Marshall Scott Lucia; Wendy Poage; Paul D Maroni; Shandra S Wilson; Leonard Michael Glodé; Paul Arangua; Jay Newmark; Mitchell Steiner; Priya N Werahera; Elward David Crawford
Journal:  Prostate       Date:  2018-02-19       Impact factor: 4.104

Review 2.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

3.  Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.

Authors:  David Ulmert; Andrew J Vickers; Howard I Scher; Charlotte Becker; Peter Iversen; David Frankel; Jens-Kristian Jensen; Tine Kold Olesen; Hans Lilja
Journal:  Clin Chem Lab Med       Date:  2012-11       Impact factor: 3.694

4.  Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.

Authors:  Susan Evans-Axelsson; David Ulmert; Anders Örbom; Pernilla Peterson; Olle Nilsson; Johan Wennerberg; Joanna Strand; Karin Wingårdh; Tomas Olsson; Zandra Hagman; Vladimir Tolmachev; Anders Bjartell; Hans Lilja; Sven-Erik Strand
Journal:  Cancer Biother Radiopharm       Date:  2012-04-10       Impact factor: 3.099

5.  Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.

Authors:  Laila Bruun; Charlotte Becker; Jonas Hugosson; Hans Lilja; Anders Christensson
Journal:  Prostate       Date:  2005-11-01       Impact factor: 4.104

6.  Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.

Authors:  Danni L Meany; Lori J Sokoll; Daniel W Chan
Journal:  Expert Opin Med Diagn       Date:  2009-11-01

7.  Novel diagnostic biomarkers for prostate cancer.

Authors:  Chikezie O Madu; Yi Lu
Journal:  J Cancer       Date:  2010-10-06       Impact factor: 4.207

Review 8.  Screening for prostate cancer: an update.

Authors:  Shahrokh F Shariat; Peter T Scardino; Hans Lilja
Journal:  Can J Urol       Date:  2008-12       Impact factor: 1.344

Review 9.  [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].

Authors:  A Haese; M Graefen; J Palisaar; E Huland; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

Review 10.  [Isoforms of free prostate-specific antigen].

Authors:  A Haese; J Noldus; T Steuber; H Huland; H Lilja
Journal:  Urologe A       Date:  2004-06       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.